---
title: "MRK: Q2 2026 sales up 5% to $16.6B, with oncology and new launches driving growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294809754.md"
description: "Q2 2026 sales rose 5% to $16.6B, led by oncology and animal health, with new launches fueling growth. Updated 2026 revenue guidance is $66.3B–$67.3B, but EPS guidance was lowered due to a $5.7B acquisition charge. Multiple pipeline and regulatory milestones were achieved.Original document: Merck & Company, Inc. [MRK] Slides Release — Aug. 4 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-04T10:52:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294809754.md)
  - [en](https://longbridge.com/en/news/294809754.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294809754.md)
generator: "portal-rs"
---

# MRK: Q2 2026 sales up 5% to $16.6B, with oncology and new launches driving growth

Q2 2026 sales rose 5% to $16.6B, led by oncology and animal health, with new launches fueling growth. Updated 2026 revenue guidance is $66.3B–$67.3B, but EPS guidance was lowered due to a $5.7B acquisition charge. Multiple pipeline and regulatory milestones were achieved.

Original document: Merck & Company, Inc. \[MRK\] Slides Release — Aug. 4 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [CNSP: Strategic pivot targets high-value oncology and neurology assets with strong financial backing](https://longbridge.com/en/news/296126240.md)
- [IMM: First-in-class immunotherapies efti and IMP761 advance in oncology and autoimmunity](https://longbridge.com/en/news/296543630.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [GRVY: 2Q 2026 saw stable revenue, strong global growth, and a first-ever KRW 30bn interim dividend](https://longbridge.com/en/news/296137591.md)
- [10:03 ET"Fundamentals of Radiation Oncology, 4th Edition" Selected for 2026 Doody's Core Titles in Radiation Oncology](https://longbridge.com/en/news/296503669.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**